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http:WHAT THIS PAPER ADDS
Our systematic review assesses outcomes of the Hemodialysis Reliable Outﬂow (HeRO) graft and discusses its
usage in complex haemodialysis patients with central venous stenosis. There have been various single centre
studies published, but this manuscript offers to combine the whole literature to date on its outcomes in terms of
patency, dialysis access associated steal syndrome, interventions, and bacteraemia. This will allow clinicians to
accurately understand the whole literature on the HeRO graft.Objectives: With improved dialysis survival there are increasing numbers of patients who have exhausted
deﬁnitive access options due to central venous stenosis and are maintaining dialysis on a central venous catheter.
The Hemodialysis Reliable Outﬂow (HeRO) allows an alternative by providing a deﬁnitive access solution. The aim
of this study is to systematically review the published outcomes of the HeRO graft and discuss the role in complex
haemodialysis patients.
Methods: Electronic databases were searched for studies assessing the use of the HeRO graft for dialysis in
accordance with PRISMA published up to December 31 2014. The primary outcomes for this study were 1-year
primary and secondary patency rates. Secondary outcomes were rates of dialysis access associated steal
syndrome, HeRO-related bacteraemia rates and rates of interventions.
Results: Following strict inclusion/exclusion criteria, eight studies including 409 patients were included in our
review. Primary and secondary pooled patency rates in this complex cohort of dialysis patients were found to be
21.9% (9.6e37.2%) and 59.4% (39.4e78%). The rate of dialysis access associated steal syndrome was low at 6.3%
(1e14.7%) as was the range of HeRO-related bacteraemia (0.13e0.7 events per 1000 days).
Conclusions: This literature review shows that the HeRO graft is an acceptable option for complex dialysis
patients who are catheter dependent. Owing to device availability, published data are predominantly North
American and further longer-term studies in other populations may be necessary. In this challenging patient
group, randomized controlled trials are required to allow comparisons with alternative access options.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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A critical factor in the survival of renal dialysis patients is
the surgical creation of deﬁnitive vascular access (VA).
Arteriovenous ﬁstulas (AVFs) are the preferred choice due
to their superior long-term outcomes1 and have been pro-
moted by guidelines, for example the ﬁstula ﬁrst initiative in
the United States.2 With improved survival of dialysis pa-
tients most clinicians will encounter a subgroup of complex
patients who may have had repeated failed AVFs or arte-
riovenous grafts (AVGs) and exhausted all upper arm
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of associated bloodstream infections, central venous ste-
nosis, and mortality.
Over the last few years, an alternative to central cathe-
ters for these complex patients has been proposed with the
Hemodialysis Reliable Outﬂow (HeRO) graft (Cryolife Inc
company; Eden Prairie, MN, USA). Comprising two ele-
ments, a graft and venous outﬂow component, the graft is
anastomosed to the ipsilateral brachial artery and tunnelled
subcutaneously. The venous outﬂow component is placed
percutaneously into the right atrium through the subclavian
or internal jugular vein and superior vena cava. This
component is tunnelled subcutaneously towards the graft.
Therefore, it bypasses central stenosis, primarily in the
brachial, cephalic, and subclavian veins by positioning the
tip of the outﬂow component beyond it in the right atrium.
The two elements are subsequently attached to each other
subcutaneously through a purpose designed titanium
connector. This then provides a deﬁnitive access with con-
tinuity from the artery through to the right atrium. None of
the catheter is exposed therefore reducing the risk of
infection (Fig. 1). The FDA approved the HeRO graft in 2008
and there are reports of its usage from North American
studies; however, it has only recently been introduced in
Europe. The aim and purpose of this review was to sys-
tematically assess the published outcomes of the HeRO
graft and discuss its usage in complex haemodialysis
patients.METHODS
Search methodology for identiﬁcation of relevant studies
Searches of Pubmed Central, Medline, Embase, and the
Cochrane Library were performed using the followingFigure 1. Illustration of HeRO graft anastomosed to the brachial
artery and inserted via right internal jugular vein into right atrium.speciﬁc search terms: HeRO graft, HeRO access, HeRO
catheter, and Hemodialysis Reliable Outﬂow graft to iden-
tify articles in English language published prior to December
31 2014, dealing primarily with the use of the HeRO graft
for dialysis. In addition, the references cited in selected
articles were reviewed for any further relevant available
studies. All studies of vascular access creation using the
HeRO graft were eligible for inclusion.
We included randomized trials and observational studies.
Exclusion criteria were published abstracts, case reports,
review articles, editorials without original data, and non-
English language publications. Articles that assessed the
grafts in non-vascular access procedures were excluded. The
systematic review was performed in accordance with
PRISMA.3 Therefore, all included studies were assessed for
inclusion on the basis of their topic, type of study, method,
number of patients included and availability of their original
results.
Primary and secondary outcomes
All studies that met the set criteria were thoroughly
reviewed and assessed for methodological quality. The two
reviewers (J.A. and N.I.) independently extracted data using
a standardized table. This was done in duplicate to increase
accuracy. If there was any difference in the extracted data,
we resolved it by consensus. Data extracted included pri-
mary and secondary outcome as well as year of publication,
number of patients included, and duration of follow-up. The
primary outcomes for this study were 1-year primary and
secondary patency rates. Secondary outcomes were rates of
early failure, dialysis access associated steal syndrome, graft
infection, HeRO-related bacteraemia rates, and rates of re-
interventions.
Statistical analysis
Characteristics and results of each included study were
compiled into a tabulated form. The inverse of the
FreemaneTukey Double Arcsine transformation9 was
applied to the primary and secondary patency rates, which
were then pooled using random effects (DerSimonian and
Laird) models.4 Weighed pooled rates were calculated with
conﬁdence intervals.
RESULTS
Ninety-eight articles and abstracts were identiﬁed using our
search strategy. After screening the contents of the ab-
stract, 24 full text articles underwent assessment for eligi-
bility and quality inspection of methodology (Fig. 2).
Following the assessment, eight articles were found to be
eligible for the review (Table 1).
As all studies were based in the United States, it is
important to look at the demographics of the patients
(Table 2) as these may be different from other countries.
The vast majority of patients were African American and
diabetic. There was no signiﬁcant difference in the number
of male and female patients. It is important to notice that
only three papers speciﬁed the mean number of previous
Figure 2. Flowsheet of results of search strategy with inclusion and exclusions following searches and screening.
Table 1. Summary of included studies and methodologies.
First author
(reference)
Study type Number of
centres
Selection bias Information bias Attrition bias Disclosures Follow-up
(months)
Katzman5 Prospective Multi-centre None
Patients had no remaining
upper limb options
None
Clear deﬁnitions
None
No patient
lost to
follow up
Industry
funded
8.6
Gage6 Retrospective Multi-centre None.
Patients had moderate
to severe central
venous stenosis/
occlusion
None.
Clear deﬁnitions
Not every
patient had
complete
outcome data
Industry
funded
12.8
Steerman7 Retrospective Single centre None
Patients had no
remaining upper
limb options
None
Clear deﬁnitions
None
No patient
lost to follow up
None 13.9
Kokkosis8 Retrospective Multi-centre None.
Patients had
central venous
occlusive disease
None.
Clear deﬁnitions
None.
No patient lost
to follow up
None 9.1
Wallace9 Retrospective Single centre None
Patients had no remaining
upper limb options
Deﬁnitions of
outcomes not
present
None
No patient lost
to follow up
None 7
Nassar10 Prospective Multi-centre Patients with
possible standard
upper limb options
could receive HeRO
None.
Clear deﬁnitions
Study terminated
early which could
be an important
factor in their
results
Industry
funded
18.5
Kudlaty11 Retrospective Single centre Patients without central
venous occlusive disease
received HeRO which is
likely to mean that they
would have standard
upper limb options
None.
Clear deﬁnitions
1 patient lost
to follow up
None 15
Torrent12 Retrospective Single centre Not clear if patients
had exhausted standard
upper limb options
None.
Clear deﬁnitions
None.
No patient lost
to follow-up
None 12.7
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Table 2. Summary table for demographic of patients of included studies.
First author
(reference)
Number
of HeRO
Age African
American (%)
Male
sex (%)
Diabetes
(%)
Previous central
catheter use (%)
Mean number of
previous accesses
BMI
Katzman5 38 62.7 37 50 68 100 5.4 29
Gage6 164 55.9 78 49 46 NS NS NS
Steerman7 60 58.2 88 49 61 100 3.1 32
Kokkosis8 12 52 73 92 46 NS NS NS
Wallace9 21 54.8 58 47 53 NS 2 NS
Nassar10 52 62.9 46 46 65 NS NS 28.9
Kudlaty11 20 57.1 91 45 60 NS NS 29.2
Torrent12 41 55 88 34 55 NS NS NS
NS ¼ not speciﬁed.
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tween 2 and 5.3.
A total of 409 HeRO grafts from eight different studies
(Table 3) have been reported so far in the literature. Mean
1-year primary and secondary patency rates were calculated
to be 21.9% (9.6e37.2%) and 59.4% (39.4e78%) respec-
tively. The pooled rate of steal syndrome from the six pa-
pers that reported its incidence was 6.3% (1e14.7%). and
device related bacteraemia (per 1,000 days) ranged be-
tween 0.13 and 0.7 in the six studies that reported it. The
rate of interventions required to maintain HeRO patency
ranged between 1.5 and three procedures per year.
DISCUSSION
In most dialysis programmes there will be patients who
have exhausted deﬁnitive access options due to central
venous stenosis and are maintaining dialysis on a central
venous catheter. A recent technological advance in vascular
access is the introduction of the HeRO device, which in-
corporates a standard dialysis graft with a 6-mm central
venous outﬂow component that is radiologically placed into
the right atrium. The two components of the device are
joined subcutaneously to create a graft from the brachial
artery that ﬂows directly into the right atrium via the
venous outﬂow section bypassing any central stenosis andTable 3. Summary table of HeRO outcomes of included studies.
Reference Number
of HeRO
Early failure
rate (%)
Primary
Patency
rate (%)
Secondary
Patency
rate (%)
Dialysis
associat
syndrom
Katzman5 38 2.6 38.9a 72.2a 2.6
Gage6 164 NS 48.8 90.8 1.4
Steerman7 60 NS 15 57 1.7
Kokkosis8 12 8.3 9.1 45.5 NS
Wallace9 21 14 11 32 22.2
Nassar10 52 3.8 34.8 67.6 3.8
Kudlaty11 20 30 29 53.5 4.8
Torrent12 41 NS 8.4 53.7 NS
Weighed
Pooled
rate %
(95% CI)
9.2
(1.9e19.9)
21.9b
(9.6e37.2)
59.4b
(39.4e78.0)
6.3 (1e
NS ¼ not speciﬁed.
a 8.6 months rates.
b Pooled rate excluding Katzman et al paper.is entirely subcutaneous with no external component as is
the case with a tunnelled catheter. Although this venous
outﬂow segment is often described as a “line” it is more
realistic in considering it a full-length central stent from
upper limb to right atrium. When considered as such, the
rationale for use of a HeRO versus multiple central venous
balloon venoplasty and stenting or for recalcitrant stenosis,
the HeRO may be a useful and cost-effective alternative to
multiple stents.
The HeRO graft has shown promise with 1-year primary
and secondary patency rates of 21.9% (9.6e37.2%) and
59.4% (39.4e78%) respectively. Although these results are
poor compared with a native AVF or AVG, in the general
dialysis population, the cohort of patients having a HeRO
placed are highly selected complex patients who have had
multiple failed AVFs or AVGs.
Alternative options include lower limbs arteriovenous
grafts (LLAVGs) that were found to have similar patency
rates in the two studies that compared them with HeRO.
Kudlaty et al.11 found that both access options are
adequate and have similar results. The study was not
randomized and the selection criteria for the procedures
were unclear, with a higher rate of diabetes and peripheral
vascular disease in the HeRO group. Despite comparable
patencies the infection rate in the LLAVG was 29%, whichaccess
ed steal
e (%)
HeRO graft
infection (%)
HeRO related
bacteraemia
per 1000 days
Rate of
intervention
per year
Mean time
with HeRO
(d/patient)
2.6 0.7 2.5 276
NS 0.14 1.5 NS
22 0.61 2.2 NS
25 NS 1.5 NS
NS 0.5 3 186
3.8 0.13 2.2 238
10 0.53 1.7 238
NS NS 2.8 380
14.7) 10.1
(2.5e21)
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describe similar rates of patency with no difference in
infection between LLAVG and HeRO; however, selection
bias with respect to BMI is stated. Those patients with
higher body mass index in the HeRO group would be much
higher risk of graft infection which may explain the differ-
ences in the studies.
If both approaches are equivalent in terms of outcome,
the cost of the device must also be considered. Although
the HeRO is initially more expensive, a health economic
study revealed that the HeRO was the least costly dialysis
access with an average 1-year cost of $6521 compared with
LLAVG ($9,567).13 These assumptions may be challenged as
they are based on data from other studies but they do serve
to guide on the costings of the two approaches.
Despite the HeRO graft being anastomosed to a proximal
artery, the evidence of dialysis access associated steal syn-
drome secondary to it is low at 6.3% (1e14.7%). This ﬁgure
is lower than that reported for proximal AVF.14 An expla-
nation may be that HeRO devices tend to be used in pa-
tients with previous access and arterial accommodation is
likely to have occurred with previous ﬁstulas and grafts. In
addition the HeRO is a long device with a 5 mm internal
diameter outﬂow which is more likely to limit ﬂow be less
prone to steal than larger conduits. Despite, this Wallace
et al.9 did show a high rate of steal syndrome in their cohort
of patients (22%). This can be explained by their small
number of patients (n ¼ 4) who all had severe pre-existing
arterial disease and required graft removal.
A concern with the volume of artiﬁcial material is infec-
tion. This analysis summarizes the HeRO-procedure-related
bacteraemia rate per 1,000 days, which ranged between
0.13 and 0.7; this is lower than the reported incidence of
catheter-related bacteraemia, which ranges between 0.6
and 6.5 episodes per 1,000 days.15,16 This would suggest an
important beneﬁt of the HeRO graft over dialysis catheters,
although many studies report lower line-related bacter-
aemia than that seen in these studies.
HeRO grafts while allowing deﬁnitive access in chal-
lenging patents do require surveillance as further endo-
vascular interventions are common, ranging from 1.5 to
three procedures per year according to the current litera-
ture. The details of interventional procedures are not
highlighted in all publications but Gebhard et al.17 describe
interventions in their series of 25 patients with HeRO
dysfunction. The majority of cases were treated with
routine management as would be applied to a thrombosed
graft. Of interest, stenoses requiring treatment were iden-
tiﬁed in 71% of procedures. Intervention for infection is the
same as for prosthetic grafts. The outﬂow segment can be
easily withdrawn and removed if required.
The current literature does have some limitation as all
studies were North American and based on a speciﬁc
population. In addition some studies had low number of
patients and some publication bias may occur in the pub-
lished studies as they represent experts and enthusiasts’
series and therefore may not reﬂect international variations
in practice.CONCLUSION
The HeRO graft is an alternative access option for complex
dialysis patients who are catheter dependent. The current
literature conﬁrms that the number of bacteraemia epi-
sodes is signiﬁcantly lower with the HeRO device than
catheters. The primary patency while low can produce
acceptable secondary patency rates following interventions.
The number of interventions required to maintain the HeRO
are similar to other series of secondary access particularly in
this especially complex population.5 Further international
studies are necessary to report the experience of the HeRO
graft in non-US populations and multicentre randomized
controlled trials to compare the graft with catheters or
alternative access procedures in such complex access
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